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Abstract: Systemic sclerosis (SSc) is an autoimmune connective tissue disease that leads to skin
fibrosis. Altered metabolism has recently been described in autoimmune diseases and SSc. Itaconate
is a product of the Krebs cycle intermediate cis-aconitate and is an immunomodulator. This work
examines the role of the cell-permeable derivative of itaconate, 4-octyl itaconate (4-OI), in SSc. SSc
and healthy dermal fibroblasts were exposed to 4-OI. The levels of collagen Nrf2-target genes and
pro-inflammatory cytokines interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) were
determined. Levels of reactive oxygen species (ROS) as well as the gene expression of collagen and
Cellular Communication Network Factor 2 (CCN2) were measured after transforming growth factor
beta 1 (TGF-β1) stimulation in the presence or absence of 4-OI. Wild-type or Nrf2-knockout (Nrf2-KO)
mouse embryonic fibroblasts (MEFs) were also treated with 4-OI to determine the role of Nrf2 in
4-OI-mediated effects. 4-OI reduced the levels of collagen in SSc dermal fibroblasts. Incubation
with 4-OI led to activation of Nrf2 and its target genes heme oxygenase 1 (HO-1) and NAD(P)H
quinone oxidoreductase 1 (NQO1). 4-OI activated antioxidant response element (ARE)-dependent
gene expression, reduced inflammatory cytokine release and reduced TGF-β1-induced collagen and
ROS production in dermal fibroblasts. The effects of 4-OI are dependent on Nrf2. The cell-permeable
derivative of itaconate 4-OI is anti-fibrotic through upregulation of Nrf2 and could be a potential
therapeutic option in an intractable disease.
Keywords: systemic sclerosis; metabolism; fibrosis; itaconate; Nrf2
1. Introduction
Systemic sclerosis (SSc) is an autoimmune idiopathic connective tissue disease that is
characterised by vascular abnormalities, inflammation and fibrosis [1,2]. The primary site
affected is the skin, but the lung can also be affected. Several studies have suggested a role
of the immune system in the activation of the fibroblasts to differentiate into myofibroblasts
that then secrete the excessive extracellular matrix that underpins the main pathology of
the disease [1]. The activated fibroblasts secrete exuberant levels of extracellular matrix
(ECM), become contractile and resistant to cell apoptosis, and this ultimately results in
fibrosis [3].
What governs the activation of a myofibroblast is not clear, but it may be a result of
failure to terminate normal physiological responses to various stimuli that are initially
beneficial but, if not appropriately terminated, result in pathological scarring. Emerging
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data have suggested a role for immunometabolism in inflammatory diseases [4]. Numer-
ous studies have suggested alterations in cellular metabolism can lead to inflammatory
diseases, including, among others, rheumatoid arthritis [5]. Itaconate, a recently described
metabolite derived from the Krebs cycle, which is generated by the enzyme aconitate
decarboxylase 1 (ACOD1) (also known as IRG1), is enormously upregulated after TLR
stimulation [6] in immune cells [7]. In a quiescent state, there are tiny amounts of itaconate,
but upon exposure to lipopolysaccharide (LPS), this can be released in millimolar levels [8].
Much work has now suggested that itaconate has an immunomodulatory role and that mice
deficient in IRG-1 have exacerbated immune disease induced by mycobacteria [9]. Further-
more, it has been found that treatment of neurons with itaconate alters the metabolic state,
which suppresses zika virus replication rates [10], and a derivative of itaconate reduced
lung inflammation [11]. Recently it was demonstrated that IRG1-deficient hepatocytes
in a hepatocyte-specific knockout mouse had enhanced liver fibrosis in vivo [12], and
we recently demonstrated that a cell-permeable derivative of itaconate, 4-octyl itaconate,
reduced collagen in dermal fibroblasts from diffuse SSc patients [13]. This work aims to
extend this observation further.
2. Materials and Methods
SSc patients with early diffuse SSc were included (n = 3). Early diffuse was defined as
<2 years from first non-Raynaud′s symptoms and positive for anti-Scl70 autoantibodies. All
patients were female and treatment naïve, and no patient had clinical evidence of interstitial
lung disease on HRCT. The study has full ethical approval with the local research ethics
committee (REC) with approval no REC/13/NE/0089 and followed the declaration of
Helsinki guidelines.
A small punch biopsy was taken from the affected fibrotic area of skin using a punch
biopsy with a local anaesthetic. SSc dermal fibroblasts were isolated and cultured in
standard fibroblast culture media, which DMEM supplemented with 10% Fetal Calf Serum
(FSC) and 1% penicillin/streptomycin (Gibco). Normal dermal fibroblasts were derived
as previously described [13]. Cells were treated with 4-octyl Itaconate (4-OI) (100 µM;
Sigma Aldrich, Poole, UK) dissolved in Dimethyl Sulfoxide (DMSO) vehicle (0.1% v/v),
and collagen was measured by the Sircol assay according to manufacturer′s instructions
(Biocolor, Belfast, Northern Ireland).
2.1. Quantitative RT-PCR
Q-RT-PCR was performed as previously described and normalised to 18S housekeep-
ing gene and shown as fold change compared to vehicle. Primer sequences are listed in
Table 1.
Table 1. Primer sequences used in this study.
Gene Forward Reverse
HO-1 5′-3′ CTGACCCATGACACCAAGGAC AAAGCCCTACAGCAACTGTCG
NQO1 5′-3′ TGGAAGCTGCAGACCTGGTG CCCTTGTCATACATGGTGGCATAC
CCN2 5′-3′ TCCCAAAATCTCCAAGCCTA GTAATGGCAGGCACAGGTCT
18S 5′-3′ GAATGGCTCATTAAATCAGTTATGG TATTAGCTCTAGAATTACCACAGTTATCC
2.2. Antioxidant Response Element (ARE) Luciferase Assay
The enzyme activity of ARE-driven luciferase as a readout of Nrf2 activity was per-
formed using an ARE luciferase construct. One µg of plasmid was transfected in pre-
confluent dermal fibroblasts using Effectene (Qiagen, Manchester UK). After 12 h, the
media were replenished, and cells were treated either with vehicle DMSO (0.1%), 4-OI
(100 µM) or sulforaphane (25 µM) for a further 24 h. The cells were then lysed, and the
luciferase activity was assessed using a luminometer. Data are expressed as a percentage
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change with untreated plasmid only set to 100%. All experiments were performed in
triplicate with four technical replicates.
2.3. ELISA
ELISA for both interleukin 6 (IL-6) and Monocyte Chemotactic Protein 1 (MCP-1)
were performed using commercial ELISA kits (R&D Systems, Oxford, UK) according to
the manufacturer′s instructions. Conditioned media were measured after stimulation of
healthy dermal fibroblasts with the TLR4 agonist LPS (100 ng/mL; Invivogen, UK) with
or without pre-treatment with 4-OI (100 µM) or vehicle. Data are from 3 independent
experiments.
ROS were measured using the cell-permeable dye CM-H2DFDA (Thermo Fisher,
Dartford, UK) that is cleaved internally, and subsequent oxidation yields a fluorescent
reporter. The dermal fibroblasts were seeded into 96 well plates treated with CM-H2DFDA
to yield the ROS reporter, then subsequently pre-treated with 4-OI (100 µM) and then
treated or not with transforming growth factor beta 1 (TGF-β1) (10 ng/mL). Fluorescence
was analysed using a fluorescence microplate reader. Data are shown as % ROS with
untreated cells set to 100%. Data are derived from 4 independent experiments.
Normal healthy dermal fibroblasts were pre-treated for 3 h with 4-OI (100 µM) and
then treated or not with TGF-β1 (10 ng/mL) or 4-OI alone for 48 h after which collagen
was quantified by the Sircol assay as previously described. Metabolic analysis was per-
formed using a Seahorse XF analyser; this measures glycolysis as a proxy for extracellular
acidification rate (ECAR) as previously described [13].
2.4. Lactate Dehydrogenase Assay (LDH)
LDH was measured as a marker of cytotoxicity in dermal fibroblasts treated or not with
vehicle or 4-OI using the cytotoxicity kit (Abcam, Ab69353) according to the manufacturer’s
instructions. A total of 50% DMSO was run alongside as a positive control.
2.5. MicroRNA Measurements
After stimulation, total RNA was isolated using miRNeasy kit using manufactures
instructions (Qiagen, Manchester, UK). miRNA was converted to cDNA using Taqman™
Advanced Reverse Transcription kit (Applied Biosystems, Dartford, UK). MiR29a was mea-
sured using Taqman™ specific primers miR29a assay id: 478587_mir (Applied Biosystems,
Dartford, UK), and miR155 was also measured by Taqman primers assay id: HS01374569_m1.
RNU44 assay id: 001094 was also quantified, and the data were normalised to RNU44
and presented as fold change. Quadruplicates were used for each individual sample.
2.6. Immunoblotting
Primary wild-type (WT) or Nrf2-knockout (Nrf2-KO) mouse embryonic fibroblast
(MEF) cells isolated from Skh-1 hairless mice [14] were maintained in a humidified 37 ◦C
incubator with 5% CO2 and grown in high-glucose DMEM (#41966, Thermo) with 10%
heat-inactivated fetal bovine serum (FBS) (Thermo) (v/v). The MEF cells were seeded at a
density of 0.5× 105 cells per well of a 12-well plate at passage 3. Sixteen hours post-seeding,
the cells were treated with either 0.1% acetonitrile (v/v) (Vehicle) or 100 µM 4-octyl itaconate
(4-OI) for 24 h. Twenty four hours after treatment with the vehicle or 4-OI, the cells were
either exposed to control buffer (TGF-β1 reconstitution buffer, 0.1% BSA in 4 mM HCl) or
stimulated with 12.5 ng/mL TGF-β1 (#100-21, Peprotech) in the presence of the vehicle
or 4-OI (100 µM) for 48 h. Cells were washed twice with PBS and lysed in 1 X SDS lysis
buffer (50 mM Tris HCl pH 6.8, 2% SDS (w/v) and 10% glycerol (v/v)). Protein content
was measured using the BCA assay (Thermo, Dartford, UK), lysates were incubated with
5% (v/v) B-mercaptoethanol for 30 min at RT. Equal amounts of protein (5–20 µg) from
each lysate is loaded and subjected to gel electrophoresis (NuPAGE 4–12% BisTris/MOPS
20-well midi gel) (Thermo Fisher, Dartford, UK) and transferred onto 0.45 µM nitrocellulose
membranes (Amersham) at 70 V for 2 h using the criterion blotter with plate electrodes
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(Biorad, UK). Subsequently, the membranes were blocked with 5% non-fat milk (w/v)
dissolved in 0.1% Tween-20 (v/v) in phosphate-buffered saline (PBST) (Milk-PBST) for 1 h
at room temperature (RT). Upon completion of blocking, membranes were incubated with
primary antibodies raised against NQO1 (1:1000 dilution in Milk-PBST, #62262, CST) and
GAPDH (1:20000 dilution in Milk-PBST, #60004-1-Ig, Proteintech, Manchester, UK) for 2 h
at RT. The membrane used for collagen detection was washed for 5 min in PBST at RT and
incubated in COL1A1 primary antibody (#AB765P, Millipore, Oxford, UK) diluted 1:1000 in
3% bovine serum albumin (BSA) (w/v) in PBST (BSA-PBST) and incubated overnight. After
primary antibody incubation, the immunoblots were washed thrice every 5 min with PBST,
after which they were incubated with their respective fluorescently labelled secondary
antibodies (LI-COR) diluted in Milk-PBST at a 1:20000 dilution for 1 h. The blots were
washed in PBST for 30 min before scanning them using the Odyssey CLx Imager (LI-COR).
3. Results
Itaconate, whilst known to be upregulated in response to TLR stimulation, has recently
been shown to be anti-inflammatory by activating Nrf2 via modification of specific cysteine
residues of its principal inhibitor Kelch-like ECH-associated protein-1 (Keap1) [15]. We re-
cently showed that the cell-permeable itaconate derivative 4-OI reduced collagen in dermal
fibroblasts from diffuse SSc patients [13], and we sought to examine that further. Incubation
of SSc fibroblasts with 4-OI reduced the collagen levels in the cell culture medium from
these cells by ~60% compared to the vehicle-treated cells (Figure 1A) (p = 0.0017 Student’s
t-test 46.3 v 20.9 µg/mL; n = 3).
We also found significant upregulation of the Nrf2-target genes heme oxygenase 1
(HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1) [16] in the 4-OI-treated cells
(Figure 1C) (n = 3). It is interesting to note that Nrf2 is significantly downregulated in SSc
dermal fibroblasts and skin biopsies, and Nrf2-deficient mice have exaggerated skin and
lung fibrosis [17]. Nrf2 is normally associated with Keap1 through direct protein–protein
interactions; this results in polyubiquitination and subsequent degradation of Nrf2 through
the proteasome [18]; in this way, Keap1 constrains activation of Nrf2 and subsequent
downstream gene expression. Molecules that modify Keap1 cause stabilisation and nuclear
translocation of Nrf2 and subsequent cytoprotective Nrf2-dependent expression of genes
containing antioxidant response elements (AREs) in their promoter sequences to restore
the homeostatic balance [19]. To confirm that 4-OI induces ARE-dependent transcription,
we transfected dermal fibroblasts with an ARE-driven luciferase reporter, and we could
see a significant increase in ARE-luciferase activity by 2-fold (p = 0.0001, Student’s t-test,
n = 4) (Figure 1C). The magnitude of this increase is similar to that caused by the known
potent Nrf2 inducer sulforaphane (Figure 1C).
Based on recent previous studies that have identified the role of itaconate as being
anti-inflammatory in macrophages—as measured by cytokine responses after LPS stim-
ulation [15,20]—we sought to determine the effect of 4-OI on the cytokine IL-6 and the
chemokine MCP-1 after TLR stimulation. Previous studies have identified these as target
proteins of TLR4 signalling in dermal fibroblasts [21]. Incubation with the TLR4 ligand LPS
led to significant upregulation of both IL-6 and MCP-1 in healthy dermal fibroblasts that
was attenuated with pre-treatment of cells with 4-OI (Figure 1D). This suggests that, like
previous studies in immune cells [8,15], itaconate possesses anti-inflammatory properties.
Both IL-6 and MCP-1 are dysregulated in SSc [22,23].
Next, we examined the levels of reactive oxygen species (ROS) after stimulation
with the pro-fibrotic cytokine transforming growth factor beta 1 (TGF-β1), highly ele-
vated in SSc [24], with prior incubation with 4-OI as Nrf2-mediated activation of the
stress response would be expected to reduce this effect. Figure 1E demonstrates that
pre-treatment with 4-OI reduced ROS induction by TGF-β1 significantly (p = 0.05 TGF-β1
versus TGF-β1 & 4-OI treatment, ANOVA, n = 4).
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Figure 1. (A). Reduced collagen in SSc fibroblast with itaconate. SSc dermal fibroblasts were cultured in vitro with 100 µM
of the cell-permeable derivative of itaconate 4-OI or not, and after 48 h, the collagen was quantified using the Sircol assay
(µg/mL). Data are the mean, and error bars are the standard deviation of the mean, and each point represents a single
donor. ** p = 0.0017 Student’s t-test n = 3. (B). Target genes of Nrf2 are upregulated by 4-OI. Healthy normal dermal
fibroblasts were cultured with or without 4-OI (100 µM); after 24 h, the cells were harvested, and the RNA was isolated and
reverse transcribed. Genes were quantified using qRT-PCR with specific primers, and data were normalised to 18S as the
housekeeping gene. Data are shown as fold change to untreated cells after normalisation to the housekeeping gene 18S. Data
are the mean fold change and standard deviation. Each data point represents a single sample. ** significantly difference
compared to untreated cultures p =< 0.005 Student’s t-test; n = 3. (C). 4-OI activates Nrf2-dependent transcription. Dermal
fibroblasts were transfected with the ARE-luciferase construct, and after 12 h, the cells were untreated or treated with 4-OI
(100 µM) or the Nrf2 activator sulforaphane (25 µM). After a further 24 h, the cells were lysed, and luciferase was measured
using a luminometer. Data are shown as % change with untreated (but plasmid transfected) set at 100%. Bars are the mean
and standard deviation p = 0.0001 Student’s t-test n = 4; **** = p < 0.0001 Sulforaphane was excluded from this analysis as this
was run only as a positive control for Nrf2 activation. (D). 4-OI reduces pro-inflammatory cytokine release. Heathy dermal
fibroblasts were cultured and pre-treated for 3 h with 4-OI (100 µM), after which they were treated with the TLR4 agonist
LPS (100 ng) for a further 24 h. Media were removed, and cytokines were measured by ELISA. Data are the mean and
standard deviation IL-6 * p =< 0.0001 Untreated vs. LPS; * p = 0.0001 LPS vs. LPS & 4-OI ANOVA n = 3. MCP-1* p =< 0.0001
Untreated vs. LPS; * p = 0.0093 LPS vs. LPS & 4-OI ANOVA n = 3. (E). 4-OI decreased ROS levels in dermal fibroblasts.
Dermal fibroblasts were cultured and preloaded with the cell-permeable dye CM-H2DCFDA in serum-free medium; the
media were then replenished with media contained untreated, TGF-β1 only, TGF-β1 and pre-treated for 3 h with 4-OI
(100 µM) or 4-OI alone (100 µM). Following a further 12 h, the cells were measured using a fluorescence plate reader. Data
are expressed as % change in ROS as per H2DCFDA fluorescence with untreated cells set at 100%. Data are the mean and
standard deviation with each point representing a single experiment. ANOVA; n = 4. NS = non significant.
Additionally, pre-treatment with 4-OI significantly reduced TGF-β1 stimulation of
collagen protein and CCN2 mRNA in healthy dermal fibroblasts (Figure 2A,B), suggesting
that this compound has an anti-fibrotic effect given the primary role of TGF-β1 in fibrosis.
This is not associated with an increase in cell death as LDH release into the media was not
increased by treatment with 4-OI. Indeed, 4-OI also reduced the TGF-β1 induced glycolysis,
as demonstrated by extracellular acidification. Treatment with 4-OI reduced ECAR by over
45% compared to TGF-β exposed cells.
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Figure 2. 4-OI reduced TGF-β1 mediated collagen induction. (A). 4-OI reduces collagen induced by
TGF-β1. Cells were cultured and pre-treated for 3 h with 4-OI the stimulated with TGF-β1 (10 ng/mL)
or untreated and 4-OI alone and after 48 h collagen was quantified using the Sircol assay. Data are the
mean and standard deviation from 3 donors. Each point is an independent experiment. * p =< 0.0001
ANOVA p = 0.0154 LPS vs. PLS & 4-OI n = 4. (B). mRNA for CCN2 was quantified by qRT-PCR
after 6 h and normalised to 18S. Data are fold change compared to untreated control, which is set to
1. Data are the mean and standard deviation. Each point is an independent experiment. * p = 0.0001
Untreated vs. TGF-β1 treated. * p =< 0.0001 TGF-β1 vs. TGF-β1 & 4-OI; * p =< 0.0001 TGF-β1 vs.
4-IO ANOVA n = 4; *** p =< 0.001, **** p =< 0.00001; NS = Non significant.
To determine the role of Nrf2 in mediating the effects of 4-OI in the regulation of
collagen expression, we used murine embryonic fibroblasts (MEFs) from either wild-type
or Nrf2-knockout mice. In wild-type cells, the collagen levels were attenuated with the
addition of 4-OI (Figure 3). By contrast, the decrease in collagen by 4-OI was abolished
in the Nrf2-KO cells, as was the increase in the Nrf2-target protein NQO1. This result
indicates that the anti-fibrotic effect of 4-OI requires Nrf2.
To determine the possible mechanism of 4-OI-mediated Nrf2-dependent reduction
in collagen, we sought to measure the expression of miR29a after 4-OI stimulation in
SSc fibroblasts. This microRNA, miR29a, was chosen as it is a potent regulator of colla-
gen1A1 [25,26] and a very powerful antifibrotic regulator, and also because Nrf2 has been
shown to regulate this microRNA [27]. Figure 4A shows that after 4-OI incubation in
dermal fibroblasts from SSc donors, there is a statistically significant ~3-fold elevation of
miR29a compared to vehicle (p =< 0.001; Student’s t-test). However, treatment with 4-OI
did not alter the expression of microRNA155, another important regulator of collagen [28]
(Figure 4B).
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Figure 3. Nrf2 is required for the 4-OI-mediated decrease in collagen type I levels in primary mouse embryonic fibroblast
cells. Primary WT or Nrf2-KO cells were treated with vehicle control or 4-OI and, after 24 h, stimulated with TGF-β1
(12.5 ng/mL) for a further 48 h. Cells were lysed, and cell lysates were subjected to immunoblotting with the indicated
antibodies.
Figure 4. miR29a but not miR155 is upregulated by 4-OI in SSc fibroblasts. (A) MicroRNA29a was quantified after vehicle
or 4-IO (100 µM) by Taqman PCR. Data are the mean and SD. **** p =< 0.001 Student’s t-test n = 4. (B). MicroRNA155 was
quantified after vehicle or 4-OI (100 µM) by Taqman PCR. Data are the mean and SD. n = 4; NS = not significant.
4. Discussion
We show here that itaconate acts in both an anti-inflammatory and anti-fibrotic manner
in dermal fibroblasts and that this is associated with upregulation of Nrf2-target genes
and a decrease in ROS levels. The fact that Nrf2 is significantly reduced in SSc cells and
skin and lung tissues [17] suggests that Nrf2 restoration through a compound such as 4-OI
would be a possible therapeutic strategy.
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4-OI is a cell-permeable derivative of itaconate that has been demonstrated to alkylate
cysteine residues on multiple proteins, including Keap1 [15], GAPDH [29] and (Receptor-
interacting serine/threonine-protein kinase 3) RIPK3 [30]. One of the primary effects
of this post-translational modification is Nrf2 activation, which in turn promotes the
resolution of inflammation to restore homeostasis. Nrf2 is a central regulator of the cellular
antioxidant response mediating the upregulation of cytoprotective proteins such as NQO1.
Using fibroblasts from Nrf2-KO mice, we could see that the elevated collagen expression
mediated by TGF-β1 was not affected by pre-treatment with 4-OI. This shows that the effect
of 4-OI is at least partly dependent on Nrf2 activation, which is in accordance with previous
studies in regard to inflammation [15]. Recently 4-OI has been demonstrated to reduce
osteoclastogenesis in an Nrf2-dependant manner [31]. Additionally, 4-OI has recently been
shown also to modify activation of the inflammasome and resultant Interleukin-1 (IL-1)
release [32]. Interestingly, a very recent study has shown that mice deficient for IRG1 (the
enzyme responsible for generation of Itaconate) have exacerbated fibrosis in the bleomycin
mouse model of fibrosis [33]. This was attributed to the macrophage component and
not the fibroblasts themselves, as reconstitution with wild-type macrophages reduced the
fibrosis [33]. We also show that 4-OI reduced pro-inflammatory proteins IL-6 and MCP-1,
both critical in SSc disease [22] and also the levels of ROS. ROS are high in SSc fibroblasts,
whereas HO1, a target of Nrf2, is low [34]. Due to the high levels of ROS and significantly
reduced levels of Nrf2 in SSc [35], the anti-fibrotic mechanisms could be impaired; indeed,
Nrf2-KO mice have exacerbated fibrosis in the bleomycin model of skin fibrosis [35]. Thus,
pharmacological strategies that restore diminished Nrf2, such as 4-OI, would be a useful
therapeutic.
Mechanistically, we examined the levels of microRNA29a after 4-OI treatment and
found them to be elevated. MicroRNA29a was chosen as it is a critical and powerful
regulator of fibrosis directly targeting collagen 1 in its 3′UTR [36] and is significantly
reduced in SSc fibroblasts [36]. Interestingly, miR155 is also a key regulator of fibrosis but
was not altered by 4-OI treatment, suggesting that there is a specificity in the response.
This specificity may be due to the fact that miR29 is a direct Nrf2 target [27]. Kurrina et al.
used Nrf2-KO mice to demonstrate the direct binding of Nrf2 to the promoter region of
miR29a [27]. We suggest here that 4-OI induced upregulation of miR29a via Nrf2 to supress
collagen expression. Nrf2 activators such as dimethyl fumarate have been demonstrated to
be anti-fibrotic in SSc fibroblasts [37], but their clinical utility may be limited; we suggest
that 4-OI could be a novel therapeutic in SSc.
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